Search results for:
Major Scottish Hospital Adopts Steriwave
UK's Largest Hip and Knee Replacement Centre Becomes First in Scotland to Adopt Steriwave® Nasal Photodisinfection Ondine Biomedical Inc. (AIM: OBI), a leader in light-activated antimicrobial therapies to prevent and treat hospital infections, together with its UK distribution partner, Mölnlycke Health Care, is pleased to announce that NHS Golden Jubilee [...]
Leeds drops SSI 78% over Mupirocin with Steriwave
Published Leeds Study Shows Steriwave® Reduced Surgical Site Infections by 78% versus standard of care using Mupirocin in High Risk Endoscopic Endonasal Skull-Base Surgery Leeds researchers conclude in published study that Steriwave nasal photodisinfection be considered for routine adoption in high risk endoscopic endonasal skull-based surgeries, as data confirms [...]
Steriwave ICU Study Outcomes Presented at CSRT2026
SMURF Feasibility Study of Nasal Photodisinfection Presented at National Respiratory Conference Ondine Biomedical Inc. ("Ondine"), a leader in light-activated antimicrobial therapies to prevent and treat hospital infections, announces that results from the SMURF feasibility pilot study ("Suppression of Microbial Burden to Reduce Pneumonia in Critical Illness") were presented at the [...]
Ondine Presented Steriwave Data at IPC 2026
Ondine Biomedical Presented Steriwave Data at Recent Infection Prevention and Control Conference (IPC 2026) Ondine Biomedical Inc. (LON: OBI), a leader in light-activated antimicrobial therapies, announces that its President and Chief Technology Officer, Dr. Nicolas Loebel, was a featured speaker at the Infection Prevention and Control ("IPC") Conference. The event [...]
ICU Study to be Presented at 2026 CACCN Conference
Steriwave ICU Study Findings Selected for Oral Presentation at National Canadian Critical Care Nursing Conference Ondine Biomedical Inc. (AIM: OBI), a global leader in light-activated antimicrobial therapies, announces that the intensive care unit ("ICU") infection study featuring Steriwave® nasal photodisinfection, published in Critical Care on 14 April 2026, has been accepted for both oral [...]
University of Ottawa Heart Institute Reduces Surgical Site Infections Following Implementation of Steriwave Nasal Photodisinfection
Ondine Biomedical Inc. (AIM: OBI), a global leader in light-activated antimicrobial therapies, announces that the University of Ottawa Heart Institute ("UOHI"), Canada's largest and foremost academic health sciences centre dedicated to cardiovascular care, found notable results in patient safety following the integration of Steriwave® nasal decolonisation into its presurgical protocols. [...]
Ondine Biomedical Announces Selection of Two Abstracts for Presentation at the 2026 World Congress on Infectious Diseases
Ondine Biomedical Inc. (LON: OBI), a leader in photodisinfection-based therapies, is pleased to announce that two of its abstracts have been accepted for poster presentation at the upcoming World Congress on Infectious Diseases, taking place 25-27 June 2026 in Barcelona, Spain. The abstracts highlight the long-term clinical and economic impact [...]
Steriwave ICU Study Shows 39.5% Pneumonia Drop
Pioneering research from Royal Columbian Hospital Foundation shows a significant decrease in pneumonia rates and establishes a new benchmark for ICU infection prevention. Ondine Biomedical Inc. (AIM: OBI) is pleased to announce that Royal Columbian Hospital Foundation (“RCHF”)’s Advancing Innovation in Medicine (“AIM”) Research Team, at one of Canada’s leading [...]
Preparing for next phase of growth
Clinical Milestones: Completed patient enrolment in the pivotal LANTERN Phase 3 U.S. trial, with results expected in Spring 2026. Real-World Evidence Expansion: SSI reduction programmes at top hospitals and real-world evidence growing globally support broader commercial opportunities. Revenue Growth and Operational Scale-up: 29% unaudited revenue growth in 2025; in-house manufacturing and facility upgrades [...]
Ondine and Mid Yorks Win Excellence in Healthcare Partnership Award
Excellence in Healthcare Partnership Award recognises proven collaboration delivering significant SSI reductions and supporting NHS priorities Ondine Biomedical Inc. and Mid Yorkshire Teaching NHS Trust (“Mid Yorks”) have won the Excellence in Healthcare Partnership Award in the Partnership Working to Address National Healthcare Priorities (Local Projects) category, recognising their collaboration to significantly [...]
For Media Information
Simon Vane Percy
Amanda Bernard
